1. Home
  2. RCEL vs JRS Comparison

RCEL vs JRS Comparison

Compare RCEL & JRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCEL
  • JRS
  • Stock Information
  • Founded
  • RCEL 2020
  • JRS 2001
  • Country
  • RCEL United States
  • JRS United States
  • Employees
  • RCEL N/A
  • JRS N/A
  • Industry
  • RCEL Medical/Dental Instruments
  • JRS Finance/Investors Services
  • Sector
  • RCEL Health Care
  • JRS Finance
  • Exchange
  • RCEL Nasdaq
  • JRS Nasdaq
  • Market Cap
  • RCEL 310.6M
  • JRS 267.5M
  • IPO Year
  • RCEL N/A
  • JRS N/A
  • Fundamental
  • Price
  • RCEL $12.87
  • JRS $9.30
  • Analyst Decision
  • RCEL Hold
  • JRS
  • Analyst Count
  • RCEL 3
  • JRS 0
  • Target Price
  • RCEL $16.50
  • JRS N/A
  • AVG Volume (30 Days)
  • RCEL 112.9K
  • JRS 86.6K
  • Earning Date
  • RCEL 11-07-2024
  • JRS 01-01-0001
  • Dividend Yield
  • RCEL N/A
  • JRS 8.87%
  • EPS Growth
  • RCEL N/A
  • JRS N/A
  • EPS
  • RCEL N/A
  • JRS N/A
  • Revenue
  • RCEL $60,040,000.00
  • JRS N/A
  • Revenue This Year
  • RCEL $34.73
  • JRS N/A
  • Revenue Next Year
  • RCEL $54.61
  • JRS N/A
  • P/E Ratio
  • RCEL N/A
  • JRS N/A
  • Revenue Growth
  • RCEL 32.24
  • JRS N/A
  • 52 Week Low
  • RCEL $7.51
  • JRS $5.95
  • 52 Week High
  • RCEL $18.93
  • JRS $8.00
  • Technical
  • Relative Strength Index (RSI)
  • RCEL 64.34
  • JRS 59.99
  • Support Level
  • RCEL $11.63
  • JRS $8.98
  • Resistance Level
  • RCEL $13.82
  • JRS $9.45
  • Average True Range (ATR)
  • RCEL 0.86
  • JRS 0.16
  • MACD
  • RCEL 0.09
  • JRS 0.02
  • Stochastic Oscillator
  • RCEL 74.46
  • JRS 80.77

About RCEL Avita Medical Inc.

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

About JRS Nuveen Real Estate Income Fund of Beneficial Interest

Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund invests primarily in income-producing common stocks, preferred stocks, convertible preferred stocks, and debt securities issued by real estate companies. At least 75% of the Fund's managed assets will be in securities rated investment grade.

Share on Social Networks: